EUVIMEDEUVIMED entdecken
Open Access

Intravenous lipid emulsions designed to meet preterm infant requirements increase plasma and tissue levels of docosahexaenoic acid and arachidonic acid in mice

Scott C Fligor, Savas T Tsikis, Thomas I Hirsch, Mikayla Quigley, Amy Pan, Hiroko Kishikawa, Paul D Mitchell, Kathleen M Gura, Mark Puder

Clinical Nutrition · 2024

DOI: 10.1016/j.clnu.2024.08.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nutrition, 2024. Verfasst von Scott C Fligor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Fat Emulsions, Intravenous, Arachidonic Acid, Mice, Inbred C57BL. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, BETH ISRAEL DEACONESS MEDICAL CENTER.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Intravenous lipid emulsions used in preterm infants contain insufficient docosahexaenoic acid (DHA) and arachidonic acid (ARA) to support normal development, resulting in deficiencies that contribute to complications of prematurity and cognitive delay. We sought to investigate the effects of new intravenous lipid emulsions designed to contain sufficient DHA and ARA to meet preterm needs, while avoiding liver toxicity. METHODS: Three new lipid emulsions (NLE A-C) were laboratory-generated using high pressure homogenization. First, a long-term experiment evaluated the impact on plasma, liver, and frontal cortex fatty acid composition compared to commercially available lipid emulsions. Lipid emulsions were administered via daily orogastric gavage to four-week-old C57Bl/6 J mice. Next, liver toxicity was evaluated in a murine model of parenteral nutrition-induced hepatosteatosis. Mice were provided an ad lib fat-free high carbohydrate diet, with intravenous lipid emulsion administration every other day for 19 days. RESULTS: Administration of commercially available lipid emulsions (soybean oil, mixed oil, or fish oil) resulted in decreased plasma and tissue levels of DHA and/or ARA compared to a chow control. The new lipid emulsions demonstrated a dose-response effect in plasma and tissue concentration of DHA and ARA. NLE C (with an approximately even DHA:ARA ratio), compared to chow, maintained similar DHA (19.2 ± 0.3 vs. 19.3 ± 0.3%, P = 1.00) and ARA (10.4 ± 0.2 vs. 9.9 ± 0.2% ARA, P = 0.75) content in frontal cortex tissue. All three new lipid emulsions prevented biochemical liver injury and pathologist-assessed hepatosteatosis; soybean oil lipid emulsion and mixed oil lipid emulsion treatment resulted in hepatosteatosis in both experiments. CONCLUSION: Long-term treatment with the new lipid emulsions in juvenile mice resulted in increased plasma and tissue DHA and/or ARA content compared to currently available lipid emulsions. The new lipid emulsions also prevented hepatosteatosis and biochemical liver injury with enteral and parenteral administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Docosahexaenoic AcidsFat Emulsions, IntravenousArachidonic AcidMice, Inbred C57BLLiverParenteral NutritionInfant, PrematureAnimalsMiceFish OilsHumansMaleSoybean OilInfant, NewbornFatty Liver

Stichwörter der Autor:innen

Arachidonic acidDocosahexaenoic acidLipid emulsionNeonatal intensive care unitParenteral nutritionPreterm infant

Substanzen

Docosahexaenoic AcidsFat Emulsions, IntravenousArachidonic AcidFish OilsSoybean Oil

Autor:innen und Institutionen

  • Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA.
  • Biostatistics and Research Design Center, Boston Children's Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA; Department of Pharmacy and the Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA, USA.
  • Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: Mark.Puder@childrens.harvard.edu.

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • BETH ISRAEL DEACONESS MEDICAL CENTER
  • Boston Children's Hospital
  • National Institutes of Health

Zitieren

APA

Fligor, S. C., Tsikis, S. T., Hirsch, T. I., Quigley, M., Pan, A., Kishikawa, H., Mitchell, P. D., Gura, K. M., & Puder, M. (2024). Intravenous lipid emulsions designed to meet preterm infant requirements increase plasma and tissue levels of docosahexaenoic acid and arachidonic acid in mice. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2024.08.019

Vancouver

Fligor SC, Tsikis ST, Hirsch TI, Quigley M, Pan A, Kishikawa H, et al. Intravenous lipid emulsions designed to meet preterm infant requirements increase plasma and tissue levels of docosahexaenoic acid and arachidonic acid in mice. Clinical Nutrition. 2024. doi:10.1016/j.clnu.2024.08.019

BibTeX
@article{Fligor2024,
  author = {Fligor, Scott C and Tsikis, Savas T and Hirsch, Thomas I and Quigley, Mikayla and Pan, Amy and Kishikawa, Hiroko and Mitchell, Paul D and Gura, Kathleen M and Puder, Mark},
  title = {Intravenous lipid emulsions designed to meet preterm infant requirements increase plasma and tissue levels of docosahexaenoic acid and arachidonic acid in mice},
  journal = {Clinical Nutrition},
  year = {2024},
  doi = {10.1016/j.clnu.2024.08.019}
}
Kostenlos starten →